Medical College of Wisconsin
CTSICores SearchResearch InformaticsREDCap

Inhaled nitric oxide therapy for pulmonary disorders of the term and preterm infant. Semin Perinatol 2016 10;40(6):356-369



Pubmed ID


Pubmed Central ID




Scopus ID

2-s2.0-84992316058   18 Citations


The 21st century began with the FDA approval of inhaled nitric oxide therapy for the treatment of neonatal hypoxic respiratory failure associated with pulmonary hypertension in recognition of the 2 randomized clinical trials demostrating a significant reduction in the need for extracorporeal support in the term and near-term infant. Inhaled nitric oxide is one of only a few therapeutic agents approved for use through clinical investigations primarily in the neonate. This article provides an overview of the pertinent biology and chemistry of nitric oxide, discusses potential toxicities, and reviews the results of pertinent clinical investigations and large randomized clinical trials including neurodevelopmental follow-up in term and preterm neonates. The clinical investigations conducted by the Eunice Kennedy Shriver NICHD Neonatal Research Network will be discussed and placed in context with other pertinent clinical investigations exploring the efficacy of inhaled nitric oxide therapy in neonatal hypoxic respiratory failure.

Author List

Sokol GM, Konduri GG, Van Meurs KP


Girija Ganesh Konduri MD Chief, Professor in the Pediatrics department at Medical College of Wisconsin

MESH terms used to index this publication - Major topics in bold

Administration, Inhalation
Biomedical Research
Bronchopulmonary Dysplasia
Extracorporeal Membrane Oxygenation
Hypertension, Pulmonary
Infant, Newborn
Infant, Premature
Infant, Premature, Diseases
Nitric Oxide
Randomized Controlled Trials as Topic
Respiratory Insufficiency
Treatment Outcome
Vasodilator Agents